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DOI 10.1016/j.ccr.2008.04.022The mechanisms regulating growth of lymphatic vessels have
recently emerged as a prominent area of cancer research be-
cause of the essential role of lymphatic vasculature in tumor
metastasis (Alitalo and Carmeliet, 2002; Alitalo et al., 2005).
VEGFR-3 is a receptor for the lymphangiogenic factors VEGF-C
and VEGF-D (Achen et al., 1998; Joukov et al., 1996), which is
expressed in all endothelia during early development but later
becomes restricted to lymphatic endothelial cells (ECs) and cer-
tain fenestrated blood vascular ECs. VEGFR-3 has been used as
a marker for lymphatic vessels along with LYVE-1, podoplanin,
and PROX1 (Stacker et al., 2002). However, VEGFR-3 is upregu-
lated in blood vascular ECs in some tumors and chronic wounds
(Paavonen et al., 2000; Partanen et al., 1999; Valtola et al., 1999).
Furthermore, new data show that VEGFR-3 contributes to angio-
genesis at least in certain tumors (Laakkonen et al., 2007).
VEGFR-3 expression in tumor cells has recently been reported
in several studies (Arinaga et al., 2003; Beierle et al., 2004; Kau-
shal et al., 2005; Leclers et al., 2006; Li et al., 2003; Witte et al.,
2002), including one published in Cancer Cell (Su et al., 2006).
These data are at odds with previously published results, includ-
ing ours (Valtola et al., 1999), and call for a reassessment of the
VEGFR-3 role in tumor metastasis. We have reinvestigated
VEGFR-3 expression in human tumors and cell lines using immu-
nohistochemical staining, FACS, RT-PCR,western, and northern
blotting analyses. None of the cancer cell lines tested, including
A549 and MDA-MB-231 cells previously reported to express
VEGFR-3, produced VEGFR-3 mRNA, whereas high levels
were present in human dermal microvascular endothelial cells
(Figure 1A). In contrast, A549, LNM-35, and the MDA-MB-231
cells expressed mRNA encoding the VEGFR-3 ligand VEGF-C.
Neither A549 nor MDA-MB-231 cells contained VEGFR-3 pro-
tein, as detected by western blotting or FACS analysis using
monoclonal antibodies 9D9F9 or 2E11D11, which recognize
the extracellular domain of VEGFR-3 (Figures 1B and 1C).
MAB3491, which was used by Su et al., detected 125 kDa and
170 kDa bands in all cell lines tested but failed to detect
VEGFR-3 in transfected 293T cells (Figure 1C). As the 293T,
A549, and MDA-MB-231 cells lacked VEGFR-3 mRNA, these
data indicate that MAB3491 recognizes a nonspecific antigen.
RT-PCR using the same set of primers as reported by Su et al.
(Figure 1D) or an alternative set of primers (data not shown) failed
to demonstrate the presence of VEGFR-3 mRNA except in the
human erythroleukemia cell line HEL and the human ovarian car-
cinoma cell line OVCAR8 (Laakkonen et al., 2007). Also, immuno-554 Cancer Cell 13, 554–556, June 2008 ª2008 Elsevier Inc.precipitation analyses failed to detect VEGFR-3 expression in
MDA-MB-231 or A549 cells (Figure 1 E). Among 62 human cell
lines tested, we have detected VEGFR-3 mRNA and protein in
the erythroleukemia HEL, the ovarian carcinoma OVCAR8 (Fig-
ures 1D and 1E), the nephroblastoma SK-NEP-1, the retinoblas-
toma Y79, and the teratocarcinoma cell line Tera2 (Pajusola
et al., 1992; Laakkonen et al., 2007). These results indicate that
the induction of VEGFR-3 in cultured tumor cell lines is a rare
event, and when observed it can be detected with the 9D9F9 an-
tibody. To study whether VEGF-C can induce a cellular response
in the absence of detectable VEGFR-3, we used a migration as-
say. As expected, VEGF-C induced migration of microvascular
endothelial cells; however, both A549 and MDA-MB-231 cells
failed to migrate in response to stimulation (Figure S1 available
online).
Finally, we stained 456 human neoplasms of 35 various histo-
logical types (Table S1), including the ones in which VEGFR-3
expression in tumor cells was reported (Arinaga et al., 2003; Li
et al., 2003; Shields et al., 2004; Su et al., 2006; Witte et al.,
2002). We detected VEGFR-3 expression only in blood or lym-
phatic vessels but not in tumor cells (Figure 1F). We have also
re-examined 40 publications reporting VEGFR-3 expression in
human tumors (Table S2) and found that all publications using
9D9F9 antibody report the expression in blood and/or lymphatic
vessels but not tumor cells. Strikingly, 90% of studies using
SantaCruz Biotechnology antibodies reported VEGFR-3 expres-
sion in tumor cells. Indeed, the polyclonal antibody sc-321, used
in at least five publications, produced strong staining of tumor
cells (Figure S2A). However, detailed examination revealed that
sc-321 stains nonspecifically both VEGFR-3-positive and -neg-
ative endothelial cells (Figure S2B), which may account for the
nonspecific staining of tumor specimens. However, the sc-321
antibody recognized VEGFR-3 by western blotting (Figure S2C;
Veikkola et al., 2003). Using a variety of retrieval procedures,
we were not able to obtain reliable staining of paraffin sections
withMAB3491, which also failed to recognize VEGFR-3 by west-
ern blotting (Figure 1C) or immunoprecipitation analysis (data not
shown). Staining of frozen sections of human tumors, where the
antigens are usually well preserved, revealed colocalization of
the 9D9F9 signal and the blood vessel marker von Willebrand
factor, as expected (Valtola et al., 1999). On the contrary,
MAB3491 produced intense staining that did not colocalize
with staining for von Willebrand factor, strongly suggesting non-
specific binding (Figure S3A). To rule out the possibility that
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frozen sections of MDA-MB-231 tumor xenografts in nude mice
using both 9D9F9 and MAB3491. However, no significant stain-
ing above the background level was observed (Figure S3B).
Except for vascular tumors (Partanen et al., 1999), the expres-
sion of VEGFR-3 is uncommon in solid tumors and instead lim-
ited to blood vascular and lymphatic endothelial cells. We there-
fore submit that the lymphatic and blood vessels, and not tumor
cells, represent the major target of anti-VEGFR-3 therapy in
cancer. Moreover, our results call for caution when using anti-
VEGFR-3 antibodies that may not be optimal for immunohisto-
chemistry of paraffin-embedded sections, as well as when inter-
preting the staining results, where signal to noise ratio should be
taken into account when evaluating staining specificity. Our data
are also a reminder that the thorough validation of antibodies
should be regarded as an absolute requirement, especially
when they produce unexpected results. Furthermore, RT-PCR
results should be interpreted carefully, as even minimal numbers
of transcripts, which do not translate into functional protein
Figure 1. Analysis of VEGFR-3 Expression
in Tumor Cell Lines and Neoplasms
(A) Northern blotting and hybridization for the
indicated transcripts in a set of tumor cell lines
and human dermal microvascular endothelial cells
(HDMEC); L and S denote the long and short
isoforms of VEGFR-3.
(B) FACS analysis of HDMECs and A549, MDA-
MB-231 cells using the 9D9F9 and 2E11D11 anti-
bodies. Note that VEGFR-3 protein (green line) is
detected only in the HDMECs.
(C) Western blotting of untransfected and VEGFR-
3 transfected 293T, A549, and MDA-MB-231 cell
lysates using the 9D9F9 and MAB3491 mono-
clonal antibodies. The same blot was reprobed
for b-actin as a loading control.
(D) RT-PCR analysis of VEGFR-3 and glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA expression in cancer cell lines. HEL and
OVCAR-8 cells were used as positive controls.
Primers BP843/BP844 were used for VEGFR-3
detection (Su et al., 2006).
(E) Immunoprecipitation and western blotting of
VEGFR-3 from A549, MDA-MB-231, and MCF-7
cells. HEL, HDMEC, and human intestinal micro-
vascular cells (HIMEC) were used as positive
controls. Lysates from VEGFR-3 transfected and
untransfected 293T cells were run in the same
gel and western blotted as an additional positive
control. Positions of unprocessed and processed
VEGFR-3 polypeptides (Pajusola et al., 1994) are
indicated.
(F) Only vascular endothelial cells express VEGFR-
3 in human neoplasms. A representative staining
of human breast carcinoma tissue array specimen
using the 9D9F9 antibodies. The inset shows
staining of a blood vessel. Scale bar, 25 mm.
levels or cellular responses, can be easily
detected. Based on the immunohisto-
chemical stainings and analyses of tumor
cell lines by flow cytometry, northern, RT-
PCR, and western blotting, we conclude
that VEGFR-3 expression by cultured cancer cells and neoplas-
tic cells in most solid tumors is negligible when compared to the
levels observed in endothelial cells.
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